International Journal of Hematology最新文献_第9页

Long-term clinical outcomes of patients with localized primary ocular adnexal mucosa-associated lymphoid tissue lymphoma. 局部原发性眼附件黏膜相关淋巴组织淋巴瘤患者的长期临床结果。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-02-11 DOI: 10.1007/s12185-026-04173-7

Ritsuko Nakai, Dai Maruyama, Akiko Miyagi-Maeshima, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Hiroshi Igaki, Shigenobu Suzuki, Kensei Tobinai, Koji Izutsu

{"title":"Long-term clinical outcomes of patients with localized primary ocular adnexal mucosa-associated lymphoid tissue lymphoma.","authors":"Ritsuko Nakai, Dai Maruyama, Akiko Miyagi-Maeshima, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki, Hiroshi Igaki, Shigenobu Suzuki, Kensei Tobinai, Koji Izutsu","doi":"10.1007/s12185-026-04173-7","DOIUrl":"https://doi.org/10.1007/s12185-026-04173-7","url":null,"abstract":"Because primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (POAML) is rare, key clinical questions, including the best treatment strategy and the validity of watchful waiting (WW), remain unresolved. Although radiotherapy (RT) is the standard treatment for localized POAML, it is commonly associated with acute and late toxicities. Overall, 128 patients with localized POAML diagnosed and managed at our institution between 1998 and 2015 were retrospectively analyzed. Forty-two patients were initially managed with WW, and 86 received immediate RT. During a median follow-up of 7.2 years (range 0.1-18.4), no patients died of lymphoma progression. Seven patients in the WW group experienced disease progression at the primary site. In the RT group, almost all patients (97.7%) achieved a complete response after RT; however, 12 patients relapsed. Histological transformation occurred in one patient in each group. The 10-year cumulative incidence of progression was 24.9% (95% CI, 12.6-45.7%) with WW and 13.1% (95% CI, 6.9-23.9%) with RT (p = 0.27). The rate of freedom from systemic therapy at 10 years was 89.7 and 94.8%, respectively (p = 0.67). This observational study suggests that WW is an acceptable treatment option for selected patients with localized POAML, with no significant differences in long-term outcomes compared with RT.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146157025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clonal expansion mechanisms in paroxysmal nocturnal hemoglobinuria. 阵发性夜间血红蛋白尿的克隆扩张机制。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-02-09 DOI: 10.1007/s12185-026-04167-5

Taroh Kinoshita

引用次数: 0

Designing immune reconstitution to prevent graft-versus-host disease: a novel therapeutic paradigm beyond T cell suppression. 设计免疫重建以预防移植物抗宿主病：一种超越T细胞抑制的新治疗范式。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-02-08 DOI: 10.1007/s12185-026-04176-4

Ken-Ichi Matsuoka

{"title":"Designing immune reconstitution to prevent graft-versus-host disease: a novel therapeutic paradigm beyond T cell suppression.","authors":"Ken-Ichi Matsuoka","doi":"10.1007/s12185-026-04176-4","DOIUrl":"https://doi.org/10.1007/s12185-026-04176-4","url":null,"abstract":"Graft-versus-host disease (GVHD) remains a major barrier to successful allogeneic hematopoietic stem cell transplantation, and its prevention requires not only suppression of early alloimmune responses but also the rational design of post-transplant immune reconstitution. The pathophysiology of GVHD has traditionally been understood based on Billingham's classical three criteria and a subsequent cytokine storm-driven, multistep model that emphasizes early tissue injury. In recent years, however, emerging concepts-including disruption of tissue tolerance in target organs and the layered reconstitution of donor T cells after transplantation, characterized by dynamic changes in fitness and exhaustion-have led to a refinement of these classical frameworks. This review summarizes recent advances, focusing on two key aspects: (1) updated local pathophysiological mechanisms, including injury to tissue stem cells and impaired regenerative capacity in target organs, disruption of the gut microbiota-metabolic network, and damage to the bone marrow hematopoietic niche; and (2) the mechanistic links between immune reconstitution and the development of acute and chronic GVHD, based on recent studies of donor T cell clonal dynamics. These insights support a shift from a unidimensional, immunosuppression-centered approach toward a novel, multidimensional therapeutic strategy that integrates organ protection, hematopoietic niche repair, and precise control of immune reconstitution.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146142278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bronchiolitis obliterans complicating follicular lymphoma: a case series and clinical insights. 闭塞性细支气管炎并发滤泡性淋巴瘤：一个病例系列和临床见解。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-02-03 DOI: 10.1007/s12185-026-04164-8

Takashi Nakamura, Kazuhito Suzuki, Masaharu Kawashima, Takeshi Saito, Hiroki Yokoyama, Atsushi Katsube, Ryoko Fukushima, Hiroto Ishii, Sayaka Oshima, Susumu Tanoue, Yo Sakayori, Iku Kamitani, Keitaro Okuda, Takanori Numata, Jun Araya, Shingo Yano

引用次数: 0

Synergistic effects of elranatamab and Juzentaihoto, Japanese traditional herbal medicine, in triple-class-exposed relapsed/refractory multiple myeloma with extramedullary disease: a case report. elranatamab与中药橘子藤对三级暴露复发/难治性多发性骨髓瘤伴髓外病变的协同作用1例

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-02-02 DOI: 10.1007/s12185-026-04172-8

Naohi Sahara, Takashi Matsunaga, Go Chie, Mai Mizusawa, Yukiko Miura, Seiichiro Kobayashi, Tomoki Fujii, Nobuhiro Ohno

{"title":"Synergistic effects of elranatamab and Juzentaihoto, Japanese traditional herbal medicine, in triple-class-exposed relapsed/refractory multiple myeloma with extramedullary disease: a case report.","authors":"Naohi Sahara, Takashi Matsunaga, Go Chie, Mai Mizusawa, Yukiko Miura, Seiichiro Kobayashi, Tomoki Fujii, Nobuhiro Ohno","doi":"10.1007/s12185-026-04172-8","DOIUrl":"https://doi.org/10.1007/s12185-026-04172-8","url":null,"abstract":"Relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD) is associated with poor prognosis and limited response to standard therapies. Elranatamab, a bispecific antibody targeting BCMA and CD3, has demonstrated clinical activity in triple-class-exposed (TCE) RRMM but remains less effective in patients with EMD. We report a case of a 67-year-old woman with TCE RRMM and aggressive EMD that progressed after two cycles of elranatamab. Following the addition of Juzentaihoto (JTT), a traditional Japanese herbal medicine, rapid symptom improvement, tumor regression, and disappearance of M-protein on immunofixation were observed. Moreover, after JTT initiation, lymphocyte and CD4-CD8bright cell counts increased rapidly and robustly, suggesting that JTT may enhance the elranatamab-induced antitumor immune response via these cells. To our knowledge, this is the first in vivo report indicating that JTT increases CD4-CD8bright lymphocyte counts in humans. JTT may enhance the efficacy of T cell-redirecting immunotherapies in RRMM by promoting cytotoxic T cell expansion. These findings warrant further investigation into the use of JTT as an adjunct to improve outcomes in patients with EMD.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146099772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database. 新诊断多发性骨髓瘤患者早期死亡率的调查：来自J-CHAEGE-MM数据库的真实世界队列的见解

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-02-01 Epub Date: 2025-10-02 DOI: 10.1007/s12185-025-04069-y

Michihide Tokuhira, Hitomi Nakayama, Kohtaro Toyama, Motoki Takano, Noriyoshi Iriyama, Atsushi Takahata, Eriko Sato, Yasutaka Senpuku, Maho Kawakami, Keigo Okada, Keisuke Tanaka, Takashi Abe, Yuki Osada, Koh Yamamoto, Junichi Watanabe, Toshiaki Hayashi, Yasunobu Sekiguchi, Yuta Kimura, Gaku Oshikawa, Masaru Nakagawa, Ken Suzuki, Takashi Kumagai, Shigeo Toyota, Katsuhiro Miura, Takayuki Ikezoe, Tomonori Nakazato, Takehiko Mori

{"title":"Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database.","authors":"Michihide Tokuhira, Hitomi Nakayama, Kohtaro Toyama, Motoki Takano, Noriyoshi Iriyama, Atsushi Takahata, Eriko Sato, Yasutaka Senpuku, Maho Kawakami, Keigo Okada, Keisuke Tanaka, Takashi Abe, Yuki Osada, Koh Yamamoto, Junichi Watanabe, Toshiaki Hayashi, Yasunobu Sekiguchi, Yuta Kimura, Gaku Oshikawa, Masaru Nakagawa, Ken Suzuki, Takashi Kumagai, Shigeo Toyota, Katsuhiro Miura, Takayuki Ikezoe, Tomonori Nakazato, Takehiko Mori","doi":"10.1007/s12185-025-04069-y","DOIUrl":"10.1007/s12185-025-04069-y","url":null,"abstract":"Although novel therapeutic agents, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies, have markedly improved outcomes in multiple myeloma (MM), the disease remains incurable and is associated with various causes of death. However, comprehensive analyses of mortality patterns, particularly early mortality, are still limited. In this study, we focused on patients who died within one year of treatment initiation (1-year group), based on data from the J-CHARGE-MM database showing that 146 out of 461 total deaths (31.7%) occurred within the first year. The most common cause of death was disease progression (43.2%), followed by infection (primarily pneumonia and sepsis), which frequently occurred within the first few months of induction therapy. Cardiac-associated events, such as heart failure and cardiac amyloidosis (including suspected cases), accounted for 14.4% of deaths, and sudden death for 7.5%. Multivariate analysis revealed that early mortality was significantly associated with age ≥ 65 years, elevated serum lactate dehydrogenase (LDH), elevated serum C-reactive protein (CRP), and poor performance status (PS ≥ 3), compared with later deaths. These findings support that early mortality in MM may be reduced through comprehensive cardiac evaluation and proactive infection prevention strategies, particularly in elderly patients with elevated CRP, elevated LDH, or poor PS.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"233-246"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries. 延长半衰期因素预防的三级预防：低收入和中等收入国家减少残疾的一种模式。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-02-01 Epub Date: 2025-10-02 DOI: 10.1007/s12185-025-04075-0

Archit S Pandharipande, Silky Jain, Anuj Singh, Shruti Verma, Eby P Baby, Hari Gaire, Sudipto Bhattacharya, Aditi Tulsiyan, Savitri Singh, Nita Radhakrishnan

{"title":"Tertiary prophylaxis with extended half-life factor prophylaxis: a model to reduce disability in low- and middle-income countries.","authors":"Archit S Pandharipande, Silky Jain, Anuj Singh, Shruti Verma, Eby P Baby, Hari Gaire, Sudipto Bhattacharya, Aditi Tulsiyan, Savitri Singh, Nita Radhakrishnan","doi":"10.1007/s12185-025-04075-0","DOIUrl":"10.1007/s12185-025-04075-0","url":null,"abstract":"Introduction: The real-world data on treatment and outcome of hemophilia patients using extended half-life products in developing countries remain scarce. This is largely due to delayed diagnosis, poor joint outcomes, increased morbidity, and limited access to prophylaxis and newer products for treatment and prevention.Aim: To analyze the response to extended half-life factor (EHL) prophylaxis in patients with severe hemophilia A and B with advanced arthropathy.Methods: Patients with severe hemophilia A and B who received EHL factor concentrates for prophylaxis at our center were included in this analysis. Data collected included bleed frequency, joint involvement, annualized bleed rate (ABR), number of hospital visits, and Hemophilia Joint Health Score (HJHS) prior to prophylaxis. Breakthrough bleeds while on prophylaxis were also recorded.Results: A total of 31 patients were started on EHL prophylaxis and followed up for a period ranging from 4 to 91 weeks. A reduction in the bleeding rate was noticed in all with significant reversal of target joints. Additionally, patients remained bleed-free during rehabilitation following joint surgery as well as psoas bleed-related compression neuropathy.Conclusion: EHL prophylaxis appears to be an effective strategy even for patients with baseline target joints with significant arthropathy, thus reducing the extent of disability in these patients.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"291-296"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"A tale of the uncommon: a case series on extramedullary plasmacytoma of the head and neck region: A single institutional study". “一个不寻常的故事：一个关于头颈部髓外浆细胞瘤的病例系列：一个单一的机构研究”。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-02-01 Epub Date: 2025-10-30 DOI: 10.1007/s12185-025-04086-x

Hema Ashok Perumal, Sevika Nagarajan, Pushpaja Kuttassery Ullattil, Makacherry Kesavan Unnikrishnan, Anoop Remesan Nair, Debnarayan Dutta

{"title":"\"A tale of the uncommon: a case series on extramedullary plasmacytoma of the head and neck region: A single institutional study\".","authors":"Hema Ashok Perumal, Sevika Nagarajan, Pushpaja Kuttassery Ullattil, Makacherry Kesavan Unnikrishnan, Anoop Remesan Nair, Debnarayan Dutta","doi":"10.1007/s12185-025-04086-x","DOIUrl":"10.1007/s12185-025-04086-x","url":null,"abstract":"Background: Extramedullary plasmacytoma is a rare tumor, that primarily occurs in the head and neck region. We report a case series on head and neck extramedullary plasmacytoma treated with radiation therapy to provide insights regarding clinical outcomes.Materials and methods: This was a retrospective study on radiation therapy outcomes in patients with head and neck extramedullary plasmacytoma treated between January 2010 and December 2024. The treatment course was evaluated, in terms of local tumor control rates and treatment-related toxicities.Results: A total of 200 plasmacytoma patients were screened, and 6 patients with extramedullary disease were included in the study. The most common site of occurrence was the larynx. Radiation therapy was administered at a dose of 45-50 Gy in 20-25 fractions. At a mean follow-up of 8 years, overall survival and disease-free survival were 8 and 7 years, respectively. A local control rate of 83% was achieved through radiation therapy alone. One of six patients progressed to multiple myeloma at 3 months; and all patients were alive as of the last follow-up.Conclusion: In head and neck extramedullary plasmacytoma, radiation offers excellent local control with acceptable toxicities while also preserving organ function.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"256-262"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145408886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Longer-than-expected survival in TP53-mutated MDS with der(5;19)(p10;q10): lessons from three cases. tp53突变MDS合并der(5;19)（p10;q10）的生存期长于预期：来自三个病例的经验教训。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-02-01 Epub Date: 2025-12-09 DOI: 10.1007/s12185-025-04133-7

Mai Fujita, Hiroshi Ureshino

引用次数: 0

Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma. polatuzumab vedotin对复发或难治性弥漫性大b细胞淋巴瘤常规化疗的疗效

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2026-02-01 Epub Date: 2025-10-15 DOI: 10.1007/s12185-025-04084-z

Tatsuzo Mishina, Chika Manako, Takeaki Sugawara, Hideki Tsujimura, Kyoya Kumagai, Masahiro Takeuchi

{"title":"Efficacy of polatuzumab vedotin versus conventional chemotherapy in relapsed or refractory diffuse large B-cell lymphoma.","authors":"Tatsuzo Mishina, Chika Manako, Takeaki Sugawara, Hideki Tsujimura, Kyoya Kumagai, Masahiro Takeuchi","doi":"10.1007/s12185-025-04084-z","DOIUrl":"10.1007/s12185-025-04084-z","url":null,"abstract":"Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) has a poor prognosis, particularly in patients ineligible for autologous stem cell transplantation or cellular immunotherapy. This study evaluated the effectiveness of polatuzumab vedotin combined with rituximab and bendamustine (PBR) therapy in comparison to conventional chemotherapy in patients with R/R DLBCL. Of 86 patients with first relapse or primary refractory DLBCL, 32 received PBR in any subsequent line, while 54 received conventional chemotherapy alone. For comparison, 32 baseline-matched patients were selected from these 54 and defined as the conventional chemotherapy group. The median overall survival (OS) for all patients was 17.3 months (range, 1.5-85.7 months), with the PBR-treated group showing significantly improved outcomes (median OS 19.7 vs. 15.8 months, P = 0.025). Univariate and multivariate analyses identified PBR as a favorable prognostic factor for OS. In the second-line setting, 41.2% of patients who received PBR were ≥ 80 years, compared with just 11.1% of those who received salvage regimens. Despite this older age distribution, the PBR group showed a trend toward favorable progression-free survival. These results suggest that PBR therapy is more effective and tolerable than conventional chemotherapy in patients with R/R DLBCL.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"208-214"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145300082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0